BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC).
Read More…
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-650-8895020
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees17
Next Earnings Date12/5/2019 (Estimated)
OptionableNot Optionable
Biopharmx (NYSEAMERICAN:BPMX) Frequently Asked Questions
What is Biopharmx's stock symbol?
Biopharmx trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BPMX."
When did Biopharmx's stock split? How did Biopharmx's stock split work?
Biopharmx shares reverse split on the morning of Friday, April 26th 2019. The 1-25 reverse split was announced on Monday, April 15th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 25th 2019. An investor that had 100 shares of Biopharmx stock prior to the reverse split would have 4 shares after the split.
How were Biopharmx's earnings last quarter?
Biopharmx Corp (NYSEAMERICAN:BPMX) released its earnings results on Monday, September, 9th. The biotechnology company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.33) by $0.11. View Biopharmx's Earnings History.
When is Biopharmx's next earnings date?
What price target have analysts set for BPMX?
2 analysts have issued 12-month price targets for Biopharmx's shares. Their predictions range from $1.00 to $1.00. On average, they expect Biopharmx's share price to reach $1.00 in the next year. This suggests a possible upside of 199.6% from the stock's current price. View Analyst Price Targets for Biopharmx.
What is the consensus analysts' recommendation for Biopharmx?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biopharmx in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biopharmx.
Has Biopharmx been receiving favorable news coverage?
Media headlines about BPMX stock have trended positive on Wednesday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Biopharmx earned a media sentiment score of 2.1 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Biopharmx.
Are investors shorting Biopharmx?
Biopharmx saw a decline in short interest in September. As of September 15th, there was short interest totalling 192,400 shares, a decline of 19.7% from the August 15th total of 239,500 shares. Based on an average daily volume of 842,500 shares, the short-interest ratio is currently 0.2 days. Approximately 1.4% of the shares of the stock are sold short. View Biopharmx's Current Options Chain.
Who are some of Biopharmx's key competitors?
Some companies that are related to Biopharmx include Crescita Therapeutics (CTX), BTC Health (BTC), Regeneus (RGS), Adalta (1AD), Destiny Pharma (DEST), Cellmid (CDY), ImmuPharma (IMM), Collagen Solutions (COS), Oncolytics Biotech (ONC), NovaBay Pharmaceuticals (NBY), Devonian Health Group (GSD), Suda Pharmaceuticals (SUD), Fusion Antibodies (FAB), biOasis Technologies (BTI) and Race Oncology (RAC).
What other stocks do shareholders of Biopharmx own?
Who are Biopharmx's key executives?
Biopharmx's management team includes the folowing people:
- Dr. David S. Tierney M.D., Pres, CEO, CFO and Director (Age 55)
- Dr. Kin Foong Chan, Exec. VP of Research & Technology (Age 45)
- Dr. José Zayas, Sr. VP of Operations
- Ms. Joyce Goto, VP, Chief Accounting Officer & Controller (Age 45)
- Ms. AnnaMarie Daniels, Exec. VP of Clinical & Regulatory Affairs
How do I buy shares of Biopharmx?
Shares of BPMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Biopharmx's stock price today?
One share of BPMX stock can currently be purchased for approximately $0.33.
How big of a company is Biopharmx?
What is Biopharmx's official website?
How can I contact Biopharmx?
Biopharmx's mailing address is 1505 Adams Dr Ste D, MENLO PARK, CA 94025-1451, United States. The biotechnology company can be reached via phone at +1-650-8895020.
MarketBeat Community Rating for Biopharmx (NYSEAMERICAN BPMX)
MarketBeat's community ratings are surveys of what our community members think about Biopharmx and other stocks. Vote "Outperform" if you believe BPMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BPMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
